The report also covers products from therapy areas such as Oncology, Infectious Disease, Toxicology, and Genetic Disorders which include the indications Solid Tumor, Human Epidermal
According to GlobalData’s company profile on Lyell Immunopharma, Cytokine activate T-cell based compositions was a key innovation area identified from patents. Lyell Immunopharma‘s grant share
CMN-005 is under clinical development by CoImmune and currently in Phase II for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma).
CMN-005 is under clinical development by CoImmune and currently in Phase II for Primary Mediastinal B-Cell Lymphoma.
CMN-005 is under clinical development by CoImmune and currently in Phase II for Nodal Marginal Zone B-Cell Lymphoma.
CMN-005 is under clinical development by CoImmune and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL).
CMN-005 is under clinical development by CoImmune and currently in Phase II for Relapsed Chronic Lymphocytic Leukemia (CLL).
CMN-005 is under clinical development by CoImmune and currently in Phase II for Follicular Lymphoma.
CMN-005 is under clinical development by CoImmune and currently in Phase II for B-Cell Non-Hodgkin Lymphoma.
Sildenafil citrate is under clinical development by XOMA Royalty and currently in Phase II for Female Hypoactive Sexual Desire Disorder.